Maxigen Biotech Inc. (TPE:1783)

Market Cap	3.57B -21.4%
Revenue (ttm)	792.49M +27.1%
Net Income	234.07M +50.7%
EPS	2.59 +49.6%
Shares Out	80.69M
PE Ratio	17.10
Forward PE	n/a
Dividend	0.83 (1.87%)
Ex-Dividend Date	Sep 5, 2025

Volume	58,935
Average Volume	135,188
Open	43.80
Previous Close	44.00
Day's Range	43.75 - 44.90
52-Week Range	35.55 - 55.00
Beta	0.26
RSI	40.29
Earnings Date	Mar 20, 2026

About Maxigen Biotech

Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices and cosmetic products in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone materials; beauty care products; and medical devices for ophthalmology, otolaryngology, dental, surgical, orthopedics, and medical aesthetics, as well as engages in collagen purification activities. It also offers ophthalmic vis...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1998
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1783

Financial Performance

In 2024, Maxigen Biotech's revenue was 680.65 million, an increase of 9.41% compared to the previous year's 622.12 million. Earnings were 190.17 million, an increase of 14.68%.